Pioneering Science to Transform Patient Care

 

 

Neurological diseases are the leading cause of disability and the second leading cause of death worldwide. We believe that no other disease area holds as much need or as much promise for medical breakthroughs.

With our focus in neurological diseases and our deep scientific expertise we are a well-established leader in the research and development of medicines that have the potential to transform neuroscience to benefit patients and society. We closed the year with 27 clinical programs; 6 in Phase 3, 12 in Phase 2 and 9 in Phase 1. Since the pharmaceutical field is vast, with many intersecting therapeutic research areas, we are using pioneering science as we continue to build our multi-franchise portfolio, with a focus on five core and four emerging growth areas.

 

 


 

 

Our core growth areas include:

  • Multiple Sclerosis and neuroimmunology
  • Alzheimer’s disease and dementia
  • Neuromuscular disorders, including spinal muscular atrophy and amyotrophic lateral sclerosis
  • Movement disorders, including Parkinson’s disease
  • Ophthalmology

 

 

Our emerging growth areas include:

  • Immunology
  • Neurocognitive disorders
  • Acute neurology
  • Pain


Learn more about our scientific expertise